Get the Stockscreener App
1.57
0.00%
0.00
Pre-market:
1.60
0.03
+1.91%
Acurx Pharmaceuticals Inc stock is traded at $1.57, with a volume of 89,936.
It is up +0.00% in the last 24 hours and down -18.23% over the past month.
Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.
See More
Previous Close:
$1.57
Open:
$1.62
24h Volume:
89,936
Relative Volume:
0.04
Market Cap:
$6.75M
Revenue:
-
Net Income/Loss:
$-7.50M
P/E Ratio:
-0.3565
EPS:
-4.4035
Net Cash Flow:
$-6.14M
1W Performance:
-6.55%
1M Performance:
-18.23%
6M Performance:
-57.45%
1Y Performance:
-74.26%
1-Day Range:
$1.57
$1.7499
1-Week Range:
$1.55
$1.7499
52-Week Range:
$1.3259
$21.00
Acurx Pharmaceuticals Inc Stock (ACXP) Company Profile
Name
Acurx Pharmaceuticals Inc
Sector
Industry
Phone
917-533-1469
Address
259 LIBERTY AVENUE, STATEN ISLAND
Compare ACXP vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACXP
Acurx Pharmaceuticals Inc
|
1.57 | 6.75M | 0 | -7.50M | -6.14M | -4.4035 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Acurx Pharmaceuticals Inc Stock (ACXP) Latest News
Certain Warrants of Acurx Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 16-JUN-2026. - marketscreener.com
ACXP Q1 2026 Earnings: Narrowed Loss Beats Estimates as Pipeline Progress ContinuesEarnings Forecast Report - newsline.com
Acurx Pharmaceuticals (ACXP) upgraded to buy: Here's why - MSN
Acurx Pharmaceuticals (ACXP) Stock Slides Slightly as Price Tests SupportMcClellan Oscillator - newsline.com
ACXP Q1 2026 Earnings: Narrower-than-Expected Loss Delivers Positive SurpriseEarnings Trend Analysis - newsline.com
Acurx Pharmaceuticals (ACXP) Upgraded to Buy: Here's Why - Yahoo Finance
Acurx Pharmaceuticals stock (US00366D1037): Nasdaq price steady as investors eye valuation metrics - AD HOC NEWS
Acurx Pharmaceuticals (ACXP) Declines 6.74% as Stock Nears Key Support at $1.71Rip Sell Trade - newsline.com
Acurx Pharmaceuticals stock (US00366D1037): Analyst consensus points to high upside from low Nasdaq - AD HOC NEWS
ACXP Q1 2026 Earnings: Narrower Loss Beats Estimates as Clinical Progress ContinuesDividend Growth Analysis - The Legal Advocate
ACXP Technical Analysis | Trend, Signals & Chart Patterns | ACURX PHARMACEUTICALS INC (NASDAQ:ACXP) - ChartMill
Acurx Pharmaceuticals (ACXP) Holds Near Key Support as Small Decline Signals ConsolidationEqual Weight ETF - newsline.com
Acurx Pharmaceuticals (ACXP) Nudges Higher as Stock Approaches ResistanceChandelier Stop - thelegaladvocate.com
Acurx Pharmaceuticals Reports First Quarter 2026 Results, Highlights Ibezapolstat Phase 3 Trial for CDI Treatment - geneonline.com
ACXP Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
ACXP Q1 2026 Earnings: Narrowed Loss Surprises as Acurx Advances Lead CandidateGuidance Upgrade Report - newsline.com
ACXP Stock Price, Quote & Chart | ACURX PHARMACEUTICALS INC (NASDAQ:ACXP) - ChartMill
Acurx Pharmaceuticals (NASDAQ: ACXP) Highlights FDA's New CDI Guidance That Could Accelerate Approval Path for Ibezapolstat - ACCESS Newswire
Earnings call transcript: Acurx Pharmaceuticals Q1 2026 sees EPS miss, stock dips - Investing.com Australia
Acurx outlines August first patient for 20-patient rCDI pilot as it weighs FDA one-trial path - MSN
Acurx Pharmaceuticals stock (US00366D1037): reverse split and price swings keep biotech in focus - AD HOC NEWS
Acurx (ACXP) Q1 2026 Earnings Transcript - AOL.com
Analysts Are Bullish on Top Healthcare Stocks: Acurx Pharmaceuticals (ACXP), Neurogene (NGNE) - The Globe and Mail
Maxim Group Maintains Acurx Pharmaceuticals(ACXP.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q1 2026 Earnings Call Transcript - Insider Monkey
Acurx Pharmaceuticals (ACXP) registers 1.3M shares for Lincoln Park resale - Stock Titan
Acurx Pharmaceuticals (NASDAQ: ACXP) registers 1.65M resale shares - Stock Titan
Acurx Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
ACURX PHARMACEUTICALS ($ACXP) Releases Q1 2026 Earnings - Quiver Quantitative
Press Release: Acurx Pharmaceuticals, Inc. Reports First Quarter 2026 Results and Provides Business Update - Moomoo
[EFFECT] Acurx Pharmaceuticals, Inc. SEC Filing - Stock Titan
TradingKey - TradingKey
Acurx Pharmaceuticals (ACXP) trims Q1 loss but flags going-concern risk - Stock Titan
ACXP Q1'26 Earnings: EPS estimate is (1.20) USD - TradingView
The growth story Acurx (ACXP) is not telling investors (Smart Money Outflows) 2026-05-08Crowd Entry Signals - newser.com
Acurx Pharmaceuticals Inc expected to post a loss of 63 cents a shareEarnings Preview - TradingView
Number of shareholders of Acurx Pharmaceuticals, Inc. – NASDAQ:ACXP - TradingView
1.65M ACXP warrant shares registered for resale by Acurx (NASDAQ: ACXP) - Stock Titan
Acurx (NASDAQ: ACXP) files S-1 to register 1.3M Lincoln Park resale shares - Stock Titan
Mouse study links Acurx antibiotics to MRSA drop, gut microbes preserved - Stock Titan
Can Acurx Pharmaceuticals (ACXP) climb 226.3% to reach the level Wall Street analysts expect? - MSN
Replay to follow Acurx CEO's virtual A.G.P. healthcare fireside chat - Stock Titan
Is Acurx Pharmaceuticals (ACXP) stock outpacing its medical peers this year? - MSN
Acurx Pharmaceuticals, Inc. To Present at The Market Movers Investor Summit - The Globe and Mail
Acurx Pharmaceuticals Inc Stock (ACXP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):